You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Granules spurts after USFDA nod for ADHD drug

Capital Market 

Granules India gained 4.68% to Rs 378 after the pharmaceutical company announced that its US subsidiary has received marketing approval from the USFDA for Dexmethylphenidate HCI extended-release capsules.

The counter trades near its all time high of Rs 383.70 hit on 10 September 2020. The stock is up 306% from its 52-week low of Rs 93 touched on 15 October 2019.

Granules India before market hours today said its US based subsidiary has received marketing approval for Dexmethylphenidate HCl extended-release capsules for the treatment of attention-deficit hyperactivity disorder (ADHD) from the US Health Regulator (FDA). Granules' capsule product is bioequivalent to the reference listed drug (RLD), Focalin XR.

The drug will be manufactured at its manufacturing facility in Chantilly, Virginia. According to IQVIA Health, Dexmethylphenidate HCI ER Capsules had US sales of approximately $556 million for the most recent twelve months ending in July 2020 (As per IQVIA MAT July 2020).

Commenting on the development, Priyanka Chigurupati, Executive Director of Granules Pharmaceuticals Inc. said the approval of Dexmethylphenidate XR is a good addition to the company's portfolio. It will be launching the product in the US market soon.

Granules is a vertically integrated pharmaceutical company, headquartered in Hyderabad, India. It produces Finished Dosages (FDs), Pharmaceutical Formulation intermediates (PFls) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, September 11 2020. 09:15 IST